long-term outcomes with tafasitamab plus lenalidomide for r/r dlbcl
Published 3 years ago • 360 plays • Length 1:31Download video MP4
Download video MP3
Similar videos
-
1:35
long-term follow-up of tafasitamab and lenalidomide in r/r dlbcl
-
1:36
the use of tafasitamab and lenalidomide in r/r dlbcl
-
1:41
real-world efficacy of tafasitamab lenalidomide in r/r dlbcl & the importance of patient selection
-
2:23
re-mind2: observational study comparing tafasitamab lenalidomide to available therapies in r/r dlbcl
-
1:45
long-term findings from mcl0208: lenalidomide maintenance post autosct in mcl
-
1:09
tafasitamab for r/r dlbcl
-
1:17
the latest updates on tafasitamab in dlbcl
-
2:22
the need for novel agents to treat patients with mcl who have relapsed after targeted therapy
-
4:46
glofitamab induces durable complete remissions in patients with relapsed large b-cell lymphoma
-
3:40
the role of dll3-directed agents in treating sclc
-
3:38
regenerating murine cd8 lung tissue resident memory t cells after targeted radiation exposure
-
8:40
lenalidomide, mutations & mds outcomes
-
2:13
tafasitamab plus lenalidomide post-cd19 car-t is associated with poor outcomes in lbcl
-
1:33
zamtocabtagene autoleucel for the treatment of patients with r/r dlbcl
-
3:36
the long-term outcomes of consolidative allosct for bpdcn
-
2:47
challenges with btki cardiotoxicity: what can be done to optimize long-term cardiac outcomes?
-
2:05
alnuctamab: improved route of administration and optimized dose level & dosing schedule
-
1:32
the use of belantamab mafodotin in triplet combinations for multiple myeloma
-
1:50
real-world outcomes of teclistamab treatment in r/r multiple myeloma
-
3:56
phase i study of tinostamustine in pre-treated patients with r/r hodgkin lymphoma
-
1:27
mitapivat increases β-thalassemic erythroblast energy production and oxidative stress responsiveness
-
2:59
improve outcomes with continuous total hemoglobin (sphb®)